Evommune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	10	13	7	5
Revenue Growth	233.33%	85.71%	40.00%	-
Gross Profit	10	13	7	5
Selling, General & Admin	28.12	20.03	12.77	10.85
Research & Development	83.77	74.04	64.24	32
Operating Expenses	111.89	94.07	77.01	42.85
Operating Income	-101.89	-81.07	-70.01	-37.85
Interest Expense	-	-0.01	-0.03	-0.06
Interest & Investment Income	7.24	3.32	3.24	3.86
Other Non Operating Income (Expenses)	-0.02	8.89	-0	-0
Pretax Income	-94.67	-68.87	-66.81	-34.05
Net Income	-94.67	-68.87	-66.81	-34.05
Preferred Dividends & Other Adjustments	-	-	1.5	-
Net Income to Common	-94.67	-68.87	-68.31	-34.05
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	23	6	2	1
Shares Outstanding (Diluted)	23	6	2	1
Shares Change	1390.45%	306.86%	20.35%	-
EPS (Basic)	-4.15	-11.22	-45.29	-27.17
EPS (Diluted)	-4.15	-11.22	-45.29	-27.17
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-74.65	-76.68	-58.28	-30.09
Free Cash Flow Per Share	-3.27	-12.49	-38.64	-24.01
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1018.94%	-623.62%	-1000.19%	-757.00%
Profit Margin	-946.68%	-529.77%	-975.83%	-681.06%
Free Cash Flow Margin	-746.54%	-589.82%	-832.61%	-601.76%
EBITDA	-100.36	-79.68	-68.73	-36.85
D&A For EBITDA	1.54	1.39	1.29	1
EBIT	-101.89	-81.07	-70.01	-37.85
Revenue as Reported	10	13	7	5

SEC Filings: 10-K · 10-Q